ArticleJournal of cardiovascular translational research2024
ASSESS-IE: a Novel Risk Score for Patients with Infective Endocarditis.
Article in Journal of cardiovascular translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Current Management of Infective Endocarditis: A Narrative Review Focused on Unmet Clinical Needs and the Multidisciplinary Approach.Journal of cardiovascular development and disease · 2026Review
- The impact of thrombocytopenia on mortality in infective endocarditis - aInternational journal of cardiology. Heart & vasculature · 2025Review
- Prediction of hospital mortality in patients with left-sided infective endocarditis using a score in the first hours of admission.Scientific reports · 2025Article
- Mortality predicting models for patients with infective endocarditis: a machine learning approach.BMC medical informatics and decision making · 2025Observational
- Infective endocarditis risk scores: a narrative review.Journal of thoracic disease · 2025Review
- Enhanced Risk Stratification in Infective Endocarditis Surgery: A Comprehensive External Validation of All Available Mortality Prediction Scores.Clinical epidemiology · 2025Article
- Metabolic Reprogramming in Cardiovascular Diseases.Journal of cardiovascular translational research · 2024Article
- FAM3A As a Potential Molecular Target to Regulate Mitochondrial Respiration and ATP Production in Ischemic Heart.Journal of cardiovascular translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mortality in patients with infective endocarditis (IE) remains high. The existing risk scores are relatively complex with limited clinical application. This study was conducted to establish a new risk model to predict in-hospital and 6-month mortality in IE patients. A total of 1549 adult patients with definite IE admitted to Guangdong Provincial People's Hospital (n=1354) or Xiamen Cardiovascular Hospital (n=195) were included. The derivation cohort consisted of 1141 patients. The score was developed using the multivariate stepwise logistic regression analysis for in-hospital death. Bootstrap analysis was used for validation. Discrimination and calibration were evaluated by the receiver operating characteristic curve and the Hosmer-Lemeshow goodness-of-fit test. Six risk factors were used as score parameters (1 point for each): aortic valve affected, previous valve replacement surgery, severe heart failure, elevated serum direct bilirubin, moderate-severe anemia and acute stage. The predictive value and calibration of the ASSESS-IE score for in-hospital death were excellent in the derivation (area under the curve [AUC]=0.781, p<0.001; Hosmer-Lemeshow p=0.948) and validation (AUC=0.779, p<0.001; Hosmer-Lemeshow p=0.520) cohorts. The score remained excellent in bootstrap validation (AUC=0.783). The discriminatory ability of the ASSESS-IE score for in-hospital (AUC: 0.781 vs. 0.799, p=0.398) and 6-month mortality (AUC: 0.778 vs. 0.814, p=0.040) were similar with that of Park's score which comprised 14 variables. The ASSESS-IE risk score is a new and robust risk-stratified tool for patients with IE, which might further facilitate clinical decision-making.
Indexed as
Identifiers
37966632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.